HRID 427273As product
Completing data — refresh the page later to see the latest
211735-76-1O=C(c1ccc2nonc2c1)N1CCCCC1XFVRBYKKGGDPAJ-UHFFFAOYSA-NFarampator is under investigation in clinical trial NCT00113022 (Org 24448 to Treat Major Depression).
211735-76-1DTXSID90175413CHEMBL1276138Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
UsesFarampator has shown effects as an AMPA receptor potentiator and glycine reuptake inhibitor with potential anti-psychotic efficacy and enhancement of prefrontal glutamatergic transmission. Farampator’s effects on both AMPA-PAMs and GlyT-1 inhibitor maybe also improve cognitive impairments in schizophrenia and in particular when combied with Risperidone (R525000).